Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform.
- Gillessen S Department of Oncology/Haematology, Kantonsspital, St. Gallen, Switzerland.
- Gilson C MRC Clinical Trials Unit, University College London, London, UK.
- James N Warwick Medical School, University of Warwick, Coventry, UK; University Hospitals Birmingham NHS Foundation Trust, The Medical School, University of Birmingham, Birmingham, UK.
- Adler A Diabetes Service, Addenbrooke's Hospital, Cambridge, UK.
- Sydes MR MRC Clinical Trials Unit, University College London, London, UK.
- Clarke N Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK. Electronic address: noel.clarke@christie.nhs.uk.
- 2016-07-25
Published in:
- European urology. - 2016
Androgen Antagonists
Drug Repositioning
Drug Therapy, Combination
Humans
Hyperglycemia
Hypoglycemic Agents
Male
Metformin
Neoplasm Metastasis
Orchiectomy
Prostatic Neoplasms
English
Metformin is a safe, well-tolerated, inexpensive treatment that can be given in addition to current standard-of-care therapies for prostate cancer. Its use might mitigate the deleterious side effects of castration and exert an additional anticancer effect. It will be incorporated in the STAMPEDE trial platform in summer 2016. This will test its true utility as a repurposed treatment for men with high-risk locally advanced or metastatic prostate cancer at first presentation.
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.1016/j.eururo.2016.07.015
- PMID 27450106
- Persistent URL
- https://sonar.ch/global/documents/278336
Statistics
Document views: 20
File downloads:
- Full-text: 0